Russell Investments Group
JANX icon

Russell Investments Group’s Janux Therapeutics JANX Stock Holding History

Russell Investments Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
81,601
+38,663
+90% +$560K ﹤0.01% 2344
2026
Q1 		$597K Buy
42,938
+21,876
+104% +$300K ﹤0.01% 2433
2025
Q4 		$291K Buy
21,062
+3,560
+20% +$83.7K ﹤0.01% 2699
2025
Q3 		$428K Sell
17,502
-38,034
-68% -$926K ﹤0.01% 2535
2025
Q2 		$1.28M Sell
55,536
-98,312
-64% -$2.59M ﹤0.01% 1940
2025
Q1 		$4.15M Buy
153,848
+152,837
+15,117% +$5.76M 0.01% 1267
2024
Q4 		$54.1K Buy
1,011
+442
+78% +$23.4K ﹤0.01% 2805
2024
Q3 		$25.8K Sell
569
-460
-45% -$20K ﹤0.01% 2909
2024
Q2 		$43.1K Buy
1,029
+1,018
+9,255% +$47.8K ﹤0.01% 2798
2024
Q1 		$414 Buy
+11
New +$240 ﹤0.01% 3231
2023
Q3 		– Sell
-1,532
Closed -$18.2K – 3572
2023
Q2 		$18.2K Hold
1,532
– – ﹤0.01% 2856
2023
Q1 		$18.5K Buy
+1,532
New +$25.5K ﹤0.01% 2824

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Russell Investments Group's JANX Position: Q2 2026 in Review

Russell Investments Group increased its Janux Therapeutics (JANX) stake by 90% in Q2 2026, buying an estimated $560K and bringing the position to 81,601 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2344.

Russell Investments Group first reported a position in JANX in Q1 2023 and has held it in 12 quarters since. The position peaked at $4.15M in Q1 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Russell Investments Group held 81,601 shares of Janux Therapeutics worth $1.25M as of Q2 2026.
  • Russell Investments Group bought 38,663 Janux Therapeutics shares in Q2 2026, an estimated $560K.
  • Janux Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2344 holding.
  • Russell Investments Group first reported a position in Janux Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Russell Investments Group's Janux Therapeutics position peaked at $4.15M in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.